JLE

European Journal of Dermatology

MENU

Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe Volume 15, numéro 5, September-October 2005

Auteurs
Universitätsklinik für Dermatologie und Venerologie, Otto-von-Guericke-Universität Magdeburg,Leipziger Str. 44, 39120 Magdeburg, Germany, Instituto Valenciano de Oncología, Profesor Beltrán Báguena, 19, 46009-Valencia, Spain, Medisch Spectrum Twente, Ariensplein 1, 7511 JX, Enschede, Netherlands, Universitätshautklinik Düsseldorf, Moorenstr.5, 40225 Düsseldorf, Germany, 3M Healthcare Limited, 3M House, Morley Street, Loughborough, LE11 1EP, United Kingdom, 3M Pharmaceuticals, 3M Center Building 275-02W-14, St. Paul, Minnesota, 55144-1000 USA

Imiquimod is an immune response modifier that acts through Toll-like receptor 7 to induce innate and cell-mediated immune responses. This ongoing phase III, open-label study conducted in Europe is evaluating the long-term (5 year) clinical efficacy and safety of imiquimod 5% cream applied once daily 5 times per week (5 ×/week) for 6 weeks for the treatment of superficial basal cell carcinoma (sBCC). A total of 182 subjects were enrolled. The initial sBCC clearance rate was 90% (12-week post treatment), whereas the proportion of subjects who were clinically clear at 2 years (current time point) was estimated to be 79.4%. Local skin/application site reactions were the most frequently reported safety findings. Initial efficacy rates of imiquimod applied 5 ×/week for 6 weeks demonstrate its clinical utility as an alternative approach to the treatment of sBCC. The recurrence rate seen to date supports ongoing follow up of subjects treated with imiquimod.